Coronavirus

Lindsay Hoyle Excerpts

Wednesday 17th June 2020 Commons Chamber

[The Secretary of State for Health and Social Care (Matt Hancock)]

I am grateful for the chance to update the House on the urgent matter of coronavirus.

Yesterday’s treatment breakthrough shows that British science is among the best in the world. As a nation, we can be incredibly proud of our scientists. The UK is home to the best clinical trials, the most advanced immunology research, and the most promising vaccine development work of any country. We have backed the science from the start, and I am sure the whole House welcomes the life-saving breakthrough that was announced yesterday. Today, I will briefly update the House on all three aspects of that national scientific effort.

First, on clinical trials, our recovery programme, which looks at the effects of existing treatments in real-world hospital settings, is the largest of its kind. As of yesterday, 11,547 NHS patients had been recruited to the programme, which is operating across 176 sites in all four nations. In Oxford University’s dexamethasone trial, over 2,000 NHS covid patients were given a course of the drug—a commonly used steroid—over 10 days. For patients who were ill enough to require oxygen, the risk of dying fell by a fifth, and for the most seriously ill patients on mechanical ventilators, the risk of dying fell by over a third.

This is an important moment in the fight against this virus, and the first time that anyone in the world has clinically proven that a drug can improve the survival chances for the most seriously ill coronavirus patients. In February we began the trial, supported by £25 million of Government funding, and in March we began recruiting patients, and started the process of building a stockpile in case the trial was successful. As of today, we have 240,000 doses in stock, and on order. That means that treatment is immediately available, and already in use on the NHS. I am incredibly proud that this discovery has happened right here in Britain, through a collaboration between the Government, the NHS, and some of our top scientists. It is not by any means a cure, but it is the best news we have had.

Throughout this crisis, our actions have been guided by the science, and that is what good science looks like: randomised control trials; rigorous and painstaking research; moving at pace, yet getting it right. The result is that we now have objective proof—not anecdotes, but proof—that this drug saves lives, and that knowledge will benefit many thousands of people all around the world.

Seven other drugs are currently being trialled as part of the recovery process, and a further nine drugs are in live clinical trials as part of the ACCORD programme, which is looking at early-stage treatments. We look forward to seeing the results of those trials. I thank everyone involved in that process, and put on the record my thanks to our deputy chief medical officer, Professor Jonathan Van-Tam, who led the work in Government, as well as to NHS clinicians, the scientific teams, and the participants in the trial who took the drug before they knew that it worked.

Our immunology research, again, is world leading. Last month I announced a new antibody testing programme to help us understand the immunological response to the disease, and whether someone acquires resistance to coronavirus once they have had it and recovered. I am part of that programme, and as of yesterday, 592,204 people have had an NHS antibody test. The nature of immunity research means that it takes time, and we must wait to see whether someone with antibodies gets reinfected. However, with every test, we improve our picture of where the virus has been, and we grow the evidence to discover whether people who have had the disease and have antibodies are at lower risk of getting or transmitting the virus again.

Crucially, that work will help to inform how we deploy a vaccine, and it is moving at pace. Earlier this week Imperial College began its first phase of human clinical trials, and 300 participants will receive doses of the vaccine. Should they develop a promising response, Imperial will move to a large phase-3 trial later this year. Yesterday, AstraZeneca signed a deal for the manufacture of the Oxford vaccine, AZD-1222, which is the world’s most advanced vaccine under development. Its progress, while never certain, is promising.

None of that happened by accident. It happened because the British Government, scientists, and the NHS put in place a large-scale, programmatic, comprehensive, well-funded, systematic, rigorous, science-led system of research and innovation. We have been working on it since the moment we first heard of coronavirus. There is more to do in this national effort, but that is how we will win the battle. We will leave no stone unturned as we search for the tools to hunt down, control, and ultimately defeat this dreadful disease.

[Mr Speaker]

May I just say to the Secretary of State that he has gone way over the allocated time? It would have been easier for him to make a statement rather than having to have an urgent question. In future, perhaps he could come forward with a statement if he needs the extra time, and I will certainly grant that and support him in doing so. Some extra time for Jonathan Ashworth as well, and for Philippa Whitford.

[Jonathan Ashworth (Leicester South) (Lab/Co-op)]

I am grateful, Mr Speaker. I welcome the news from the Secretary of State about Dexamethasone. As he said, this is an important moment and good news, and I congratulate all those involved. It is a reminder that we can be immensely proud of our science base in this country. I note what the Secretary of State said about vaccinations. A vaccine is crucial, and I hope he will join me—I am sure he will—in saying that when a vaccine is available, we must have no truck with those who spread poisonous anti-vax propaganda on social media. Vaccinations save lives, and ultimately that will be the exit strategy from this dreadful, horrific disease.



The good news is tempered by the high death rate. The Prime Minister likes to boast of flattening the sombrero, and it is certainly true that deaths from hospitalisations are coming down, but we still have 58,000 excess deaths across England and 13,000 in care homes; and 300 health and care staff have sadly lost their lives. All our NHS staff deserve great praise, so may I ask the Health Secretary about a specific matter that has emerged in the past couple of days? Why are student nurses who joined the frontline six months ago as part of the coronavirus effort now seeing their paid placement schemes terminated early, leaving them with no income? That is no way to treat student nursing staff.

This week, the World Health Organisation has warned that the UK remains in a “very active phase of the pandemic”.

The right hon. Gentleman will accept that if a second wave comes, especially if it coincides with flu season, that would be completely disastrous. Can he reassure the House that the decisions that he and the Prime Minister are making on easing lockdown measures, such as the mooted relaxation of the 2-metre rule and the opening of non-essential retail this week, will not precipitate a deadly second wave of the virus? Would he update us on the latest thinking on that by the Home Department? In the past, the right hon. Gentleman has said that he is prepared to institute local lockdowns, but local authorities continue to say that they do not have the resources or powers to enforce that. Can he update us on when he will give local authorities powers to enforce those lockdowns?

Yesterday, the Health Service Journal said that for people in the shielding group, shielding will come to an end at the end of July. We were promised a full update on shielding on 15 June, two days ago. Can the right hon. Gentleman update the House now on what is happening and what the future is for the shielding group with regards to getting their medicines and supplies and whether they will be able to leave their homes by the end of July?

We have always said that testing, tracing and isolating is crucial to the safe easing of the lockdown. On testing, local authorities say that they are still not getting the specific test data that they need. Indeed, the Deloitte contract, as confirmed in a written answer from the Minister for Patient Safety, Mental Health and Suicide Prevention, did not specify that it needed to report test results to GPs and local directors of public health. We need to fix that.

Why is the right hon. Gentleman still not publishing the number of people who have been tested, and can he explain something that is puzzling many of us? The tracing figures that he revealed—we are grateful for them—suggested that 8,000 people went into the contact tracing system in England, but in that week, the Government testing figures said that there were around 12,500 positive cases in the UK. Even if we can make an assumption about how many of those cases are in England, that still suggests that there are around 2,000, perhaps 3,000, cases not being traced and contacted. Can he explain why that is and what he is going to do to fix it?

Finally, we have now seen Public Health England recommendations on the impact of covid on those from black, Asian and minority ethnic communities. Those recommendations are welcome. Many of them, such as mandated ethnicity data collection and recordings on death certificates, should have been done years ago, but when will those recommendations be implemented? Black people are nearly four times as likely to die from covid as white people, and over 90% of doctors who have died during the pandemic were from black, Asian and minority ethnic communities, so surely this is a matter of urgency. We cannot wait, and we need those recommendations to be implemented straight away.

--- Later in debate ---

[Matt Hancock]

The Chair of the Health and Social Care Committee makes an incredibly important point. The approach we are taking is a targeted one of repeat testing, which has started already but needs to spread much further. The reason is that some people in hospital settings are at higher risk, and it is better to focus the resources for repeat testing on those at higher risk. For instance, somebody working in finance might be at lower risk than somebody in a frontline setting. The NHS has a strategy on this, and I will write to him with further details of how that is going to work.

[Mr Speaker]

We are now heading to the SNP spokesperson, Dr Phillipa Whitford, with some extra time.

[Dr Philippa Whitford (Central Ayrshire) (SNP) [V]]

I, too, welcome the positive outcome of the recovery trial showing the contribution of dexamethasone—a drug that is cheap and accessible across the world.

Despite claiming to be well prepared for this epidemic, the Secretary of State has struggled to provide sufficient personal protective equipment to NHS staff in England. He has now awarded £350 million of PPE contracts, but can he explain why £108 million of that was awarded, without being advertised, to Crisp Websites Ltd, which trades as PestFix, a small pest extermination company? Why was such a large contract awarded to a company with no expertise in trading or supplying any PPE, let alone highly specialised equipment for NHS staff? How do the Government think that such a small company, with only £18,000 of registered assets, can manage the cash flow required to procure £108 million-worth of PPE? Is this not just a reprise of the Seaborne Freight scandal—the ferry company with no ships?

--- Later in debate ---

[Matt Hancock]

My hon. Friend is quite right. The NHS is open, and if people need NHS treatment, please come forward. If people are advised by a clinician to go to hospital, please do that.

[Mr Speaker]

Including A&E. I call Chi Onwurah.

[Chi Onwurah (Newcastle upon Tyne Central) (Lab)]

Absent a vaccine, the key to unlocking our economic and social lives is an effective test, trace and isolate system. The app, which can really help save lives, is behind schedule, so can the Secretary of State update us on the Isle of Wight trial, and specifically whether it has raised issues with the technology on Apple and/or Android phones; the levels of take-up; and an idea as to when it will be more widely available?

[Matt Hancock]

As well as being a huge enthusiast for the A&E in Chorley and working on that, Mr Speaker, I am also a huge enthusiast for the use of technology. The No. 1 lesson we learned from the Isle of Wight was that it is important to get the human contact first and use the technology to underpin the human contact tracing. What is interesting is that we are learning that to persuade people to isolate—it is obvious really—a human contact, a phone call with a real person on the other end, is the best way to do it. We have a much higher number of contact tracers per head of population in this country now than almost any of our comparators.

[Mr Speaker]

I am pleased the Secretary of State is a fan of Chorley A&E: we look forward to it opening very shortly. I call Flick Drummond.

[Mrs Flick Drummond (Meon Valley) (Con)]

I welcome the psychological first aid training that my right hon. Friend launched this week so that frontline workers can support people with mental health problems. However, I am also concerned about the mental health of key workers themselves, particularly those in the NHS who have been working non-stop since January, many with last-minute rota changes and no prospect of a break soon. Will my right hon. Friend outline what we are doing to support key workers at this difficult time?

[Matt Hancock]

Yes. My hon. Friend makes an incredibly important point, which is that the mental health of our key workers, including those working in the NHS and social care, is incredibly important. One of the things we put in place in the crisis is a hotline. That support should have been there long before, frankly, and we will maintain it for as long as possible, because is so important to support the physical and mental health of the carers who care for us.

[Mr Speaker]

In order to allow the safe exit of hon. Members who have been participating in this item of business and the safe arrival of those participating in the next, I am now suspending the House for three minutes.

Sitting suspended.